Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Genetic screening for iron blood disorder feasible in the workplace

Screening for a condition called haemochromatosis, where iron builds up in the body, could help prevent organ damage and disease, suggests a study published online today by The Lancet.

News image

fiogf49gjkf04

People who inherit 2 copies of a mutation in a gene called HFE are predisposed to haemochromatosis.

The disorder, which affects one in 200 north Europeans, causes the body to absorb and store too much iron.

If untreated, the disorder can result in liver cirrhosis, heart problems, diabetes, arthritis and chronic fatigue.

Genetic screening for the condition is controversial because not everyone who has the mutation develops the disorder, and insurers and employers may discriminate against carriers of the mutation causing anxiety about screening.

In this study, Kate Allen and colleagues from the Murdoch Children’s Research Institute in Australia, took cheek brush samples from 11,800 adults in their workplace.

The researchers screened the samples for the HFE mutation and identified 47 participants who had 2 copies of the mutation and 1338 who had 1 copy of the mutation.

46 of the 47 newly identified carriers took steps to prevent or treat iron accumulation
The Lancet

The research team noted that 46 of the 47 newly identified carriers took steps to prevent or treat iron accumulation.

The team observed that almost all the participants were pleased they had the test and there was no increased anxiety in the individuals who had 2 copies of the gene.

In addition, the investigators reported that all individuals who had the gene mutation and sought insurance had their policies underwritten at normal standard rates.

This was due to an agreement the researchers had with the Australian insurance industry to ensure mutation carriers were not discriminated against.

Dr Allen’s team concluded, “Health economic considerations are vital to decisions regarding screening programmes.”

"An economic analysis of this programme is currently ongoing.”

“If genetic screening is shown to be cost-effective, it should be implemented since hereditary haemochromatosis can be prevented by simple measure, and, as shown in our study, the risks of such screening are very low and genetic discrimination need not occur.”

In an accompanying comment, Professor Paul Adams from the London Health Sciences Center in Canada states, "This study is a strong endorsement for the feasability and acceptability of genetic testing for haemochromatosis in the workplace."

"It is likely that optimum screening strategies, including no screening, will vary in different countries depending on various medical, ethical, legal and social issues."

Lancet 2005: embargoed for 00:01H (London time) Tuesday, April 26
27 April 2005

Go to top of page Email this page Email this page to a colleague

 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us